Answers are grounded in this paper and cite their sources.
There are more opportunities to perform human leukocyte antigen (HLA) -haploidentical stem cell transplantation and cord blood transplantation, and such procedures have become quicker. Since the management of infection and graft-versus-host disease (GVHD) has recently improved, the number of HLA-mismatched transplantations has increased. The HLA-Flow method detects mismatched HLA antigens between donor and recipient using specific anti-HLA antibodies, and analyzes mixed chimerism by flow cytometry. When recipient-derived cells are detected, their cell surface markers can be analyzed. Therefore, the HLA-Flow method is very valuable in early diagnosis of engraftment failure and relapse of leukemia, and in monitoring the number of tumor cells in a rapid and convenient manner. Loss of mismatched HLA in leukemia cells can be estimated using the combination of donor-specific HLA markers and leukemia markers. Since the HLA-Flow method provides a way of detecting chimerism at a high accuracy and high sensitivity, detection of microchimerism in peripheral blood after organ transplantation has become possible. If anti-HLA IgG-isotype antibodies with high affinity can be produced instead of commercially available IgM antibodies with low affinity, the HLA-Flow method is expected to become more prevalent.
No takes yet. Share an insight, caveat, or question.
Sato et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: